ISIN | LU1769088235 |
---|---|
Valor Number | 40150861 |
Bloomberg Global ID | UBSBIOQ LX |
Fund Name | UBS (Lux) Equity Fund - Biotech (USD) (EUR) Q-acc |
Fund Provider |
UBS Asset Management Switzerland AG, Zurich
Basel, Switzerland Phone: +41 61 288 75 01 E-Mail: sh-ubs-funds-feedback@ubs.com Web: www.ubs.com/fonds |
Fund Provider | UBS Asset Management Switzerland AG, Zurich |
Representative in Switzerland |
UBS Fund Management (Switzerland) AG Basel Phone: +41 61 288 49 10 |
Distributor(s) |
UBS Global Asset Management Basel Phone: +41 61 288 20 20 |
Asset Class | Equities |
EFC Category | Equity Global Advanced Markets |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The Fund’s investment objective consists in generating strong capital appreciation with a reasonable level of income, while giving due consideration to capital security and the liquidity of the Fund’s assets. UBS Asset Management categorises this sub-fund as an ESG Integration fund that does not promote particular ESG characteristics or pursues a specific sustainability or impact objective. The sub-fund mainly invests in shares and other equity interests of companies focusing on research, product development, product manufacture and distribution in the biotechnology industry and related sectors. The investments can be made in equities and equity interests of large multinationals or other companies whose products are not yet ready for marketing. Investments are made worldwide without restrictions. For the aforementioned reasons, units in this sub-fund may occasionally exhibit substantial price fluctuations. |
Peculiarities |
Current Price * | 100.58 EUR | 27.09.2024 |
---|---|---|
Previous Price * | 100.17 EUR | 26.09.2024 |
52 Week High * | 110.89 EUR | 29.07.2024 |
52 Week Low * | 83.21 EUR | 27.10.2023 |
NAV * | 100.58 EUR | 27.09.2024 |
Issue Price * | 100.58 EUR | 27.09.2024 |
Redemption Price * | 100.58 EUR | 27.09.2024 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 433,834,607 | |
Unit/Share Assets *** | 61,025 | |
Trading Information SIX |
YTD Performance | +1.76% |
29.12.2023 - 27.09.2024
29.12.2023 27.09.2024 |
---|---|---|
YTD Performance (in CHF) | +2.98% |
29.12.2023 - 27.09.2024
29.12.2023 27.09.2024 |
1 month | -3.22% |
27.08.2024 - 27.09.2024
27.08.2024 27.09.2024 |
3 months | -4.10% |
27.06.2024 - 27.09.2024
27.06.2024 27.09.2024 |
6 months | +0.78% |
27.03.2024 - 27.09.2024
27.03.2024 27.09.2024 |
1 year | +8.08% |
27.09.2023 - 27.09.2024
27.09.2023 27.09.2024 |
2 years | +0.01% |
04.01.2023 - 27.09.2024
04.01.2023 27.09.2024 |
3 years | - | - |
5 years | - | - |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Regeneron Pharmaceuticals Inc | 9.78% | |
---|---|---|
Vertex Pharmaceuticals Inc | 9.76% | |
Alnylam Pharmaceuticals Inc | 6.79% | |
Moderna Inc | 6.54% | |
Neurocrine Biosciences Inc | 5.09% | |
Amgen Inc | 4.76% | |
AbbVie Inc | 3.85% | |
Guardant Health Inc | 3.67% | |
argenx SE ADR | 3.36% | |
Roivant Sciences Ltd Ordinary Shares | 3.25% | |
Last data update | 31.08.2024 |
TER | 1.07% |
---|---|
TER date | 30.11.2023 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 0.82% |
Ongoing Charges *** | 1.10% |
SRRI ***
|
|
SRRI date *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |